Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.

Haines DE, Mead-Salley M, Salazar M, Marchlinski FE, Zado E, Calkins H, Yarmohammadi H, Nademanee K, Amnueypol M, Skanes AC, Saklani P.

J Interv Card Electrophysiol. 2013 Sep;37(3):233-9. doi: 10.1007/s10840-013-9800-z. Epub 2013 Jun 6.

PMID:
23740224
2.

Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.

Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR.

J Interv Card Electrophysiol. 2013 Sep;37(3):241-7. doi: 10.1007/s10840-013-9793-7. Epub 2013 Apr 28.

PMID:
23625091
3.

Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision.

Noheria A, Asirvatham SJ.

J Interv Card Electrophysiol. 2013 Sep;37(3):209-11. doi: 10.1007/s10840-013-9821-7. Epub 2013 Jul 28. No abstract available.

PMID:
23892446
4.

Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.

Steinberg BA, Hasselblad V, Atwater BD, Bahnson TD, Washam JB, Alexander JH, Daubert JP, Piccini JP.

J Interv Card Electrophysiol. 2013 Sep;37(3):213-21. doi: 10.1007/s10840-013-9813-7. Epub 2013 Jul 24.

5.

Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.

Imamura K, Yoshida A, Takei A, Fukuzawa K, Kiuchi K, Takami K, Takami M, Itoh M, Fujiwara R, Suzuki A, Nakanishi T, Yamashita S, Matsumoto A, Hirata K.

J Interv Card Electrophysiol. 2013 Sep;37(3):223-31. doi: 10.1007/s10840-013-9801-y. Epub 2013 Apr 14.

6.

Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.

Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, Mansour MC, D'Avila A, Sanchez JE, Burkhardt JD, Chalhoub F, Mohanty P, Coffey J, Shaik N, Monir G, Reddy VY, Ruskin J, Natale A.

J Am Coll Cardiol. 2012 Mar 27;59(13):1168-74. doi: 10.1016/j.jacc.2011.12.014. Epub 2012 Feb 1.

7.

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.

Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA.

Europace. 2014 Oct;16(10):1443-9. doi: 10.1093/europace/euu196. Epub 2014 Aug 12.

8.

Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.

ProvidĂȘncia R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N, Narayanan K, Marijon E, Boveda S.

Heart. 2014 Feb;100(4):324-35. doi: 10.1136/heartjnl-2013-304386. Epub 2013 Jul 22. Review.

9.

Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin.

Konduru SV, Cheema AA, Jones P, Li Y, Ramza B, Wimmer AP.

J Interv Card Electrophysiol. 2012 Dec;35(3):277-84; discussion 284. doi: 10.1007/s10840-012-9719-9. Epub 2012 Sep 27.

PMID:
23015216
10.

Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.

Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, Martin DO, Hussein A, Khoury M, Abi-Saleh B, Alam S, Sengupta J, Borek PP, Baranowski B, Niebauer M, Callahan T, Varma N, Chung M, Tchou PJ, Kanj M, Dresing T, Lindsay BD, Wazni O.

Circ Arrhythm Electrophysiol. 2013 Jun;6(3):460-6. doi: 10.1161/CIRCEP.113.000320. Epub 2013 Apr 3. Erratum in: Circ Arrhythm Electrophysiol. 2013 Oct;6(5):e79.

11.

A comparison of bleeding complications post-ablation between warfarin and dabigatran.

Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F.

J Interv Card Electrophysiol. 2012 Oct;35(1):29-33. doi: 10.1007/s10840-012-9708-z. Epub 2012 Aug 7.

PMID:
22869389
12.

A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.

Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Inden Y, Hirayama H, Murohara T.

Pacing Clin Electrophysiol. 2013 Feb;36(2):172-9. doi: 10.1111/pace.12036. Epub 2012 Nov 4.

PMID:
23121681
13.

Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.

Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N, Hayano M, Nishiuchi S, Fuke E, Miki Y, Nakamura K, Yamashita E, Kumagai K, Oshima S, Tada H.

Circ J. 2012;76(10):2337-42. Epub 2012 Jun 30.

14.

Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.

Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE, Garbati MA, Bahmaid RA, Wimmer AP.

Europace. 2013 Oct;15(10):1412-20. doi: 10.1093/europace/eut239. Epub 2013 Aug 16. Review.

PMID:
23954918
15.

The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran.

Ichiki H, Oketani N, Ishida S, Iriki Y, Okui H, Maenosono R, Namino F, Ninomiya Y, Miyata M, Hamasaki S, Tei C.

Pacing Clin Electrophysiol. 2013 Nov;36(11):1328-35. doi: 10.1111/pace.12195. Epub 2013 Aug 16.

PMID:
23952291
16.

Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.

ProvidĂȘncia R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, Hireche H, Morais J, Boveda S.

Europace. 2014 Aug;16(8):1137-44. doi: 10.1093/europace/euu007. Epub 2014 Feb 18.

PMID:
24550347
17.

Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.

Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, Crawford T, Suwanagool A, Sinno M, Carrigan T, Kennedy R, Saint-Phard W, Yokokawa M, Good E, Bogun F, Pelosi F Jr, Morady F, Oral H.

Heart Rhythm. 2013 Apr;10(4):483-9. doi: 10.1016/j.hrthm.2012.12.011. Epub 2012 Dec 11.

PMID:
23237911
18.

Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.

Maddox W, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ, Gunter A, McElderry HT.

J Cardiovasc Electrophysiol. 2013 Aug;24(8):861-5. doi: 10.1111/jce.12143. Epub 2013 Apr 11.

PMID:
23577951
19.

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.

Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators..

Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14. Erratum in: Circulation. 2012 Sep 4;126(10):e160. Heidbuchle, Hein [corrected to Heidbuchel, Hein].

20.

Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.

Stepanyan G, Badhwar N, Lee RJ, Marcus GM, Lee BK, Tseng ZH, Vedantham V, Olgin J, Scheinman M, Gerstenfeld EP.

J Interv Card Electrophysiol. 2014 Jun;40(1):33-8. doi: 10.1007/s10840-014-9888-9. Epub 2014 Mar 19.

PMID:
24643666

Supplemental Content

Support Center